Immunic initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Immunic (IMUX) with a Buy rating and $7 price target The company is advancing vidofludimus calcium, an oral multiple sclerosis therapy that combines “validated” DHODH inhibition with direct Nurr1 activation to deliver both peripheral anti-inflammatory and central neuroprotective effects, the analyst tells investors in a research note. Guggenheim sees “substantial upside” in Immunic shares if vidofludimus confirms its “differentiated efficacy and best-in-disease safety” in Phase III studies.